Drugs / BPI-361175
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05393466 | Jul 2026 → Jan 2028 expected | non-small cell lung carcinoma | Xcovery Holdings, Inc. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT05329298 | Jul 2021 → Jun 2023 | non-small cell lung carcinoma | Betta Pharmaceuticals Co., Ltd. | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-12-05 | Betta Pharmaceuticals Co., Ltd. | Regulatory 贝达药业第四代EGFR抑制剂BPI-361175 在美国获批临床 bettapharma.com ↗
近日，贝达药业收到美国食品药品监督管理局（FDA）签发的新药临床试验批准通知书，公司申报的 BPI-361175 片用于治疗携带 EGFR C797S 突变及其他 EGFR 相关突变的非小细胞肺癌的药品临床试验申请已取得美国FDA批准。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-12-05 | Betta Pharmaceuticals Co., Ltd. | 贝达药业第四代EGFR抑制剂BPI-361175 在美国获批临床 bettapharma.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BPI-361175 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05393466 ↗ |
| Action | Inhibit | “BPI-361175 is an oral fourth-generation EGFR inhibitor.” NCT05393466 ↗ |
| Route | Oral | “Patients receive BPI-361175 PO.” NCT05329298 ↗ |
| Target | EGFR | “BPI-361175 is an oral fourth-generation EGFR inhibitor.” NCT05393466 ↗ |